Koninklijke Philips N.V. provided sales guidance for the quarter and full year 2021. Comparable sales are expected to decline approximately 10% in the quarter mainly due to these effects and including the impact of the earlier announced Respironics recall.

Sales for the full year 2021 are expected to be approximately EUR 17.2 billion, which is a 1% comparable decline.